Relapsed and refractory Hodgkin Lymphoma: Transplantation strategies and novel therapeutic options

Current Treatment Options in Oncology

Volumn 8, Issue 5, 2007, Pages 352-374

  David, Kevin A ^a   Mauro, Lauren ^a   Evens, Andrew M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACLIZUMAB Y 90; DEXAMETHASONE; ETOPOSIDE; FLUDARABINE; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IFOSFAMIDE; MDX 060; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; MONOCLONAL ANTIBODY; N (2 AMINOPHENYL) 4 [4 (3 PYRIDINYL) 2 PYRIMIDINYLAMINOMETHYL]BENZAMIDE; NAVELBINE; PLATINUM COMPLEX; RADIOPHARMACEUTICAL AGENT; RITUXIMAB; SGN 30; THYMOCYTE ANTIBODY; UNINDEXED DRUG; VINCRISTINE; X LINKED INHIBITOR OF APOPTOSIS; ANTINEOPLASTIC AGENT;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; DONOR LYMPHOCYTE INFUSION; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG RESPONSE; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; ISOTOPE LABELING; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RADIATION INJURY; RADIOIMMUNOTHERAPY; REVIEW; SECOND CANCER; SURVIVAL RATE; TUMOR BIOPSY; WHOLE BODY RADIATION; ADJUVANT THERAPY; ALLOTRANSPLANTATION; METHODOLOGY; MORTALITY; RISK ASSESSMENT; SALVAGE THERAPY; TREATMENT FAILURE; TUMOR RECURRENCE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HODGKIN DISEASE; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PROGNOSIS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SALVAGE THERAPY; TRANSPLANTATION, HOMOLOGOUS; TREATMENT FAILURE;

EID: 43549091850     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-007-0046-9     Document Type: Review

References (96)

1. Cancer Facts and Figures. Atlanta: American Cancer Society, 2007
2. Diehl V, Stein H, Hummel M, Zollinger R, Connors JM: Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematology Am Soc Hematol Educ Program 2003, 225-247
3. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Bezjak A, Wells WA et al. 2005 Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 23: 4634
4. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P 2004 ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: Long-term results. J Clin Oncol 22:2835
5. Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M et al. 2003 Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: Results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. J Clin Oncol 21:3601
6. Sieniawski M, Franklin J, Nogova L, Glossmann JP, Schober T, Nisters-Backes H et al. 2007 Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma. J Clin Oncol 25:2000
7. Duggan DB, Petroni GR, Johnson JL, Glick JH, Fisher RI, Connors JM et al. 2003 Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: Report of an intergroup trial. J Clin Oncol 21:607
8. Gobbi PG, Levis A, Chisesi T, Broglia C, Vitolo U, Stelitano C et al. 2005 ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: Final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. J Clin Oncol 23:9198
9. Canellos GP, Anderson JR, Propert KJ, Nissen N, Cooper MR, Henderson ES et al. 1992 Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 327:1478
10. Longo DL, Duffey PL, Young RC, Hubbard SM, Ihde DC, Glatstein E et al. 1992 Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: The low probability for cure. J Clin Oncol 10:210
11. Josting A, Rudolph C, Mapara M, Glossmann JP, Sienawski M, Sieber M et al. 2005 Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: Results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Ann Oncol 16:116
12. Lavoie JC, Connors JM, Phillips GL, Reece DE, Barnett MJ, Forrest DL et al. 2005 High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: Long-term outcome in the first 100 patients treated in Vancouver. Blood 106: 1473
13. Moskowitz CH, Nimer SD, Zelenetz AD, Trippett T, Hedrick EE, Filippa DA et al. 2001 A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 97: 616
14. Evens AM, Altman JK, Mittal BB, Hou N, Rademaker A, Patton D et al. 2007 Phase I/II trial of total lymphoid irradiation and high-dose chemotherapy with autologous stem-cell transplantation for relapsed and refractory Hodgkin's lymphoma. Ann Oncol 18: 679
15. Scheinpflug K, Schmitt J, Jentsch-Ullrich K, Roessner A, Franke A 2003 Thymic hyperplasia following successful treatment for nodular-sclerosing Hodgkin's disease. Leuk Lymphoma 44: 1615
16. Aparicio J, Segura A, Garcera S, Oltra A, Santaballa A, Yuste A et al. 1999 ESHAP is an active regimen for relapsing Hodgkin's disease. Ann Oncol 10: 593
17. Moskowitz CH, Kewalramani T, Nimer SD, Gonzalez M, Zelenetz AD, Yahalom J 2004 Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy-proven primary refractory Hodgkin's disease. Br J Haematol 124:645
18. Ferme C, Mounier N, Divine M, Brice P, Stamatoullas A, Reman O et al. 2002 Intensive salvage therapy with high-dose chemotherapy for patients with advanced Hodgkin's disease in relapse or failure after initial chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 Trial. J Clin Oncol 20:467
19. Schmitz N, Pfistner B, Sextro M, Sieber M, Carella AM, Haenel M et al. 2002 Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: A randomised trial. Lancet 359: 2065
20. Santoro A, Magagnoli M, Spina M, Pinotti G, Siracusano L, Michieli M et al. 2007 Ifosfamide, gemcitabine, and vinorelbine: A new induction regimen for refractory and relapsed Hodgkin's lymphoma. Haematologica 92: 35
21. Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A et al. 1993 Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: Results of a BNLI randomised trial. Lancet 341:1051
22. Popat U, Hosing C, Saliba RM, Anderlini P, van Besien K, Przepiorka D et al. 2004 Prognostic factors for disease progression after high-dose chemotherapy and autologous hematopoietic stem cell transplantation for recurrent or refractory Hodgkin's lymphoma. Bone Marrow Transplant 33: 1015
23. Sureda A, Arranz R, Iriondo A, Carreras E, Lahuerta JJ, Garcia-Conde J et al. 2001 Autologous stem-cell transplantation for Hodgkin's disease: results and prognostic factors in 494 patients from the Grupo Espanol de Linfomas/Transplante Autologo de Medula Osea Spanish Cooperative Group. J Clin Oncol 19:1395
24. Czyz J, Dziadziuszko R, Knopinska-Postuszuy W, Hellmann A, Kachel L, Holowiecki J et al. 2004 Outcome and prognostic factors in advanced Hodgkin's disease treated with high-dose chemotherapy and autologous stem cell transplantation: A study of 341 patients. Ann Oncol 15: 1222
25. Gutierrez-Delgado F, Holmberg L, Hooper H, Petersdorf S, Press O, Maziarz R et al. 2003 Autologous stem cell transplantation for Hodgkin's disease: Busulfan, melphalan and thiotepa compared to a radiation-based regimen. Bone Marrow Transplant 32: 279
26. Horning SJ, Chao NJ, Negrin RS, Hoppe RT, Long GD, Hu WW et al. 1997 High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: Analysis of the Stanford University results and prognostic indices. Blood 89: 801
27. Sureda A, Constans M, Iriondo A, Arranz R, Caballero MD, Vidal MJ et al. 2005 Prognostic factors affecting long-term outcome after stem cell transplantation in Hodgkin's lymphoma autografted after a first relapse. Ann Oncol 16: 625
28. Sweetenham JW, Taghipour G, Milligan D, Blystad AK, Caballero D, Fassas A et al. 1997 High-dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 20:745
29. Nademanee A, O'Donnell MR, Snyder DS, Schmidt GM, Parker PM, Stein AS et al. 1995 High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: Results in 85 patients with analysis of prognostic factors. Blood 85: 1381
30. Engelhardt BG, Holland DW, Brandt SJ, Chinratanalab W, Goodman SA, Greer JP et al. 2007 High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: Prognostic features and outcomes. Leuk Lymphoma 48: 1728
31. Reece DE, Barnett MJ, Shepherd JD, Hogge DE, Klasa RJ, Nantel SH et al. 1995 High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood 86: 451
32. Andre M, Henry-Amar M, Pico JL, Brice P, Blaise D, Kuentz M et al. 1999 Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin's disease induction failure: A case-control study. Societe Francaise de Greffe de Moelle. J Clin Oncol 17: 222
33. Lazarus HM, Rowlings PA, Zhang MJ, Vose JM, Armitage JO, Bierman PJ et al. 1999 Autotransplants for Hodgkin's disease in patients never achieving remission: A report from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol 17: 534
34. Sweetenham JW, Carella AM, Taghipour G, Cunningham D, Marcus R, Della Volpe A et al. 1999 High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: Results in 175 patients reported to the European Group for Blood and Marrow Transplantation. Lymphoma Working Party. J Clin Oncol 17: 3101
35. Czyz J, Hellmann A, Dziadziuszko R, Hansz J, Gozdzik J, Holowiecki J et al. 2002 High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group. Bone Marrow Transplant 30: 29
36. Constans M, Sureda A, Terol MJ, et al.: Autologous Stem Cell transplantation for Primary refractory Hodgkin's disease: Results and clinical variables affecting outcome. Ann Oncol 2003, 14(5): 745
37. Josting A, Haverkamp H, Borchmann P, Döhner H, Metzner B, Franke A et al.: Fourth interim analysis of the HD-R2 study-A European multicenter trial for patients with relapsed Hodgkin lymphoma. Presented at the Seventh International Symposium on Hodgkin Lymphoma, Cologne, 2007
38. Castagna L, Magagnoli M, Balzarotti M, Sarina B, Siracusano L, Nozza A et al. 2007 Tandem high-dose chemotherapy and autologous stem cell transplantation in refractory/relapsed Hodgkin's lymphoma: A monocenter prospective study. Am J Hematol 82: 122
39. Yahalom J, Gulati SC, Toia M, Maslak P, McCarron EG, O'Brien JP et al. 1993 Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease. J Clin Oncol 11:1062
40. Tsang RW, Gospodarowicz MK, Sutcliffe SB, Crump M, Keating A 1999 Thoracic radiation therapy before autologous bone marrow transplantation in relapsed or refractory Hodgkin's disease. PMH Lymphoma Group, and the Toronto Autologous BMT Group. Eur J Cancer 35: 73
41. Wendland MM, Asch JD, Pulsipher MA, Thomson JW, Shrieve DC, Gaffney DK 2006 The impact of involved field radiation therapy for patients receiving high-dose chemotherapy followed by hematopoietic progenitor cell transplant for the treatment of relapsed or refractory Hodgkin disease. Am J Clin Oncol 29:189
42. Pezner RD, Nademanee A, Niland JC, Vora N, Forman SJ 1995 Involved field radiation therapy for Hodgkin's disease autologous bone marrow transplantation regimens. Radiother Oncol 34: 23
43. Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D et al. 2005 Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation. Lancet 365: 1934
44. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Donato M, Giralt S et al. 2005 Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: Low transplant-related mortality and impact of intensity of conditioning regimen. Bone Marrow Transplant 35: 943
45. Todisco E, Castagna L, Sarina B, Mazza R, Anastasia A, Balzarotti M et ]al. 2007 Reduced-intensity allogeneic transplantation in patients with refractory or progressive Hodgkin's disease after high-dose chemotherapy and autologous stem cell infusion. Eur J Haematol 78: 322
46. Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE et al. 1996 Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. J Clin Oncol 14: 572
47. Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH 1996 Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol 14: 1291
48. Anderson JE, Litzow MR, Appelbaum FR, Schoch G, Fisher LD, Buckner CD et al. 1993 Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: The 21-year Seattle experience. J Clin Oncol 11: 2341
49. Akpek G, Ambinder RF, Piantadosi S, Abrams RA, Brodsky RA, Vogelsang GB et al. 2001 Long-term results of blood and marrow transplantation for Hodgkin's lymphoma. J Clin Oncol 19: 4314
50. Carella AM, Beltrami G, Carella M Jr, Corsetti MT, Scalzulli RP, Greco M 2001 Immunosuppressive non-myeloablative allografting as salvage therapy in advanced Hodgkin's disease. Haematologica 86: 1121
51. Sureda A.: Reduced intensity allogeneic stem cell transplantation (RIC-Allo) for refractory/relapsed Hodgkin's lymphoma (HL).preliminary results of an EBMT prospective trial. Abstract 1064. Presented at the Seventh International Symposium on Hodgkin Lymphoma, Cologne, Germany, 2007
52. Hahn T, Benekli M, Wong C, Moysich KB, Hyland A, Michalek AM et al. 2005 A prognostic model for prolonged event-free survival after autologous or allogeneic blood or marrow transplantation for relapsed and refractory Hodgkin's disease. Bone Marrow Transplant 35: 557
53. Josting A, Franklin J, May M, Koch P, Beykirch MK, Heinz J et al. 2002 New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 20: 221
54. Stiff PJ, Unger JM, Forman SJ, McCall AR, LeBlanc M, Nademanee AP, Bolwell BJ, Fisher RI (2003) The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory Hodgkin disease: A Southwest Oncology Group phase II trial. Biol Blood Marrow Transplant 9:529
55. Jabbour E, Hosing C, Ayers G, Nunez R, Anderlini P, Pro B et al. 2007 Pretransplant positive positron emission tomography/gallium scans predict poor outcome in patients with recurrent/refractory Hodgkin lymphoma. Cancer 109:2481
56. Schot BW, Zijlstra JM, Sluiter WJ, van Imhoff GW, Pruim J, Vaalburg W et al. 2007 Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma. Blood 109: 486
57. Svoboda J, Andreadis C, Elstrom R, Chong EA, Downs LH, Berkowitz A et al. 2006 Prognostic value of FDG-PET scan imaging in lymphoma patients undergoing autologous stem cell transplantation. Bone Marrow Transplant 38: 211
58. Andre M, Henry-Amar M, Blaise D, Colombat P, Fleury J, Milpied N et al. 1998 Treatment-related deaths and second cancer risk after autologous stem-cell transplantation for Hodgkin's disease. Blood 92: 1933
59. Forrest DL, Hogge DE, Nevill TJ, Nantel SH, Barnett MJ, Shepherd JD et al. 2005 High-dose therapy and autologous hematopoietic stem-cell transplantation does not increase the risk of second neoplasms for patients with Hodgkin's lymphoma: A comparison of conventional therapy alone versus conventional therapy followed by autologous hematopoietic stem-cell transplantation. J Clin Oncol 23: 7994
60. Borchmann P, Treml JF, Hansen H, Gottstein C, Schnell R, Staak O et al. 2003 The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood 102: 3737
61. Cerveny CG, Law CL, McCormick RS, Lenox JS, Hamblett KJ, Westendorf LE et al. 2005 Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics. Leukemia 19: 1648
62. Ansell SM, Horwitz SM, Engert A, Khan KD, Lin T, Strair R et al. 2007 Phase I/II study of an anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's lymphoma and anaplastic large-cell lymphoma. J Clin Oncol 25: 2764
63. Younes A, Forero-Torres A, Bartlett N, Leonard JP, Rege B, Kennedy DA, et al.: A novel antibody-drug conjugate, SGN-35 (anti-CD30-Auristatin), induces objective responses in patients with relapsed or refractory Hodgkin lymphoma: Preliminary results of a phase I tolerability study. Abstract 099. Presented at the Seventh International Symposium on Hodgkin Lymphoma, Cologne, 2007
64. Ekstrand BC, Lucas JB, Horwitz SM, Fan Z, Breslin S, Hoppe RT et al. 2003 Rituximab in lymphocyte-predominant Hodgkin disease: Results of a phase 2 trial. Blood 101: 4185
65. Rehwald U, Schulz H, Reiser M, Sieber M, Staak JO, Morschhauser F et al. 2003 Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: Results of a phase 2 trial of the German Hodgkin Lymphoma Study Group. Blood 101: 410
66. Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rudiger T, et al.: Rituximab in relapsed lymphocyte-predominant Hodgkin Lymphoma: Long-term results of a phase-II trial of the German Hodgkin Lymphoma Study Group (GHSG). Blood 2008, 111:109
67. Younes A, Romaguera J, Hagemeister F, McLaughlin P, Rodriguez MA, Fiumara P et al. 2003 A pilot study of rituximab in patients with recurrent, classic Hodgkin disease. Cancer 98: 310
68. Klimm B, Schnell R, Diehl V, Engert A 2005 Current treatment and immunotherapy of Hodgkin's lymphoma. Haematologica 90: 1680
69. Vriesendorp HM, Quadri SM, Wyllie CT, Lai J, Borchardt PE, Harris L et al. 1999 Fractionated radiolabeled antiferritin therapy for patients with recurrent Hodgkin's disease. Clin Cancer Res 5: 3324s
70. Decaudin D, Levy R, Lokiec F, Morschhauser F, Djeridane M, Kadouche J et al. 2007 Radioimmunotherapy of refractory or relapsed Hodgkin's lymphoma with 90Y-labelled antiferritin antibody. Anticancer Drugs 18:725
71. Schnell R, Dietlein M, Staak JO, Borchmann P, Schomaecker K, Fischer T et al. 2005 Treatment of refractory Hodgkin's lymphoma patients with an iodine-131-labeled murine anti-CD30 monoclonal antibody. J Clin Oncol 23: 4669
72. O'Mahony D, Janik JE, Carrasquillo JA, Brechbiel M, Paik CH, Le N, et al.: Yttrium-90 radiolabeled humanized anti-CD25 monoclonal antibody, daclizumab, provides effective therapy for refractory and relapsed Hodgkin's lymphoma. Abstract 1060. Presented at the Seventh International Symposium on Hodgkin Lymphoma, Cologne, 2007
73. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W et al. 1997 Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest 100: 2961
74. Re D, Thomas RK, Behringer K, Diehl V 2005 From Hodgkin disease to Hodgkin lymphoma: Biologic insights and therapeutic potential. Blood 105: 4553
75. Re D, Kuppers R, Diehl V 2005 Molecular pathogenesis of Hodgkin's lymphoma. J Clin Oncol 23: 6379
76. Zhao X, Qiu W, Kung J, Zhao X, Peng X, Yegappan M, et al.: Bortezomib induces caspase-dependent apoptosis in Hodgkin lymphoma cell lines and is associated with reduced c-FLIP expression: A gene expression profiling study with implications for potential combination therapies. Leuk Res 2007. Pre published Jol 18 (a pub ahead of print)
77. Zheng B, Georgakis GV, Li Y, Bharti A, McConkey D, Aggarwal BB et al. 2004 Induction of cell cycle arrest and apoptosis by the proteasome inhibitor PS-341 in Hodgkin disease cell lines is independent of inhibitor of nuclear factor-kappaB mutations or activation of the CD30, CD40, and RANK receptors. Clin Cancer Res 10: 3207
78. Kashkar H, Deggerich A, Seeger JM, Yazdanpanah B, Wiegmann K, Haubert D et al. 2007 NF-kappaB-independent down-regulation of XIAP by bortezomib sensitizes HL B cells against cytotoxic drugs. Blood 109: 3982
79. Blum KA, Johnson JL, Niedzwiecki D, Canellos GP, Cheson BD, Bartlett NL 2007 Single agent bortezomib in the treatment of relapsed and refractory Hodgkin lymphoma: Cancer and leukemia Group B protocol 50206. Leuk Lymphoma 48: 1313
80. Younes A, Pro B, Fayad L 2006 Experience with bortezomib for the treatment of patients with relapsed classical Hodgkin lymphoma. Blood 107: 1731
81. Trelle S, Sezer O, Naumann R, Rummel M, Keller U, Engert A et al. 2007 Bortezomib in combination with dexamethasone for patients with relapsed Hodgkin's lymphoma: Results of a prematurely closed phase II study (NCT00148018). Haematologica 92: 568
82. Rosato RR, Almenara JA, Grant S 2003 The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63: 3637
83. Mathas S, Lietz A, Anagnostopoulos I, Hummel F, Wiesner B, Janz M et al. 2004 c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 199: 1041
84. Younes A, Fanale M, Pro B, McLaughlin P, Neelapu S, Fayad L et al. 2007 A phase II study of a novel oral isotype-selective histone deacetylase (HDAC) inhibitor in patients with relapsed or refractory Hodgkin lymphoma. J Clin Oncol 2007 ASCO Annu Meet Proc Part I 25: 8000
85. LaCasse EC, Cherton-Horvat GG, Hewitt KE, Jerome LJ, Morris SJ, Kandimalla ER et al. 2006 Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis. Clin Cancer Res 12: 5231
86. Kashkar H, Seeger JM, Hombach A, Deggerich A, Yazdanpanah B, Utermohlen O et al. 2006 XIAP targeting sensitizes Hodgkin lymphoma cells for cytolytic T-cell attack. Blood 108: 3434
87. Johnston PB, Ansell SM, Colgan JP, Habermann TM, Inwards DJ, Markovic SN, et al.: Promising results for patients with relapsed or refractory Hodgkin lymphoma related with the oral MTOR inhibitor everolimus (RAD001). Abstract 099. Presented at the Seventh International Symposium on Hodgkin Lymphoma, Cologne, 2007
88. Georgakis GV, Li Y, Rassidakis GZ, Martinez-Valdez H, Medeiros LJ, Younes A et al. 2006 Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death. Clin Cancer Res 12: 584
89. Skinnider BF, Elia AJ, Gascoyne RD, Trumper LH, von Bonin F, Kapp U et al. 2001 Interleukin 13 and interleukin 13 receptor are frequently expressed by Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 97: 250
90. Juszczynski P, Ouyang J, Monti S, Rodig SJ, Takeyama K, Abramson J et al. 2007 The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 104: 13134
91. Vogelstein B, Lane D, Levine AJ 2000 Surfing the p53 network. Nature 408: 307
92. Drakos E, Thomaides A, Medeiros LJ, Li J, Leventaki V, Konopleva M et al. 2007 Inhibition of p53-murine double minute 2 interaction by nutlin-3A stabilizes p53 and induces cell cycle arrest and apoptosis in Hodgkin lymphoma. Clin Cancer Res 13: 3380
93. Kawakami M, Kawakami K, Kioi M, Leland P, Puri RK 2005 Hodgkin lymphoma therapy with interleukin-4 receptor-directed cytotoxin in an infiltrating animal model. Blood 105: 3707
94. Bollard CM, Straathof KC, Huls MH, Leen A, Lacuesta K, Davis A et al. 2004 The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin disease. J Immunother (1997) 27: 317
95. Bollard CM, Aguilar L, Straathof KC, Gahn B, Huls MH, Rousseau A et al. 2004 Cytotoxic T lymphocyte therapy for Epstein-Barr virus + Hodgkin's disease. J Exp Med 200: 1623
96. Portis T, Longnecker R 2004 Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/ Akt pathway. Oncogene 23: 8619